2023年4月24日

公司增加了多个医疗行业领导人顾问委员会3月16日,2022(佛蒙特州的伯灵顿)——Biocogniv数字诊断公司专注于预测时序要求严格的医疗条件使用人工智能(AI)的实验室数据,今天宣布关闭6美元滚滚种子轮由布雷耶资本,在Y Combinator的参与下,1984年企业,改变健康、Promus投资,该基金在草裙舞,以及几个著名天使投资人,包括波士顿科技公司的创始人约翰银白杨,IBM的前首席执行官彭明盛LabCorp前执行副总裁CMO和全封闭Myla Lai-Goldman, MD,佩奇。艾未未的前首席执行官利奥格雷迪博士和Syapse的创始人和前总统乔纳森·赫希。作为此轮融资的一部分,Myla Lai-Goldman,利奥格雷迪,和乔纳森·赫希也将加入Biocogniv的顾问委员会。“在医院,每小时的延迟保健可能导致长期发病率和,在某些情况下,死亡。例如与脓毒症——在美国住院死亡的主要原因,推迟或不恰当的护理有相当于前列腺癌死亡率负担,造成每年有超过30000的美国人,“说Biocogniv首席执行官、前美国国立卫生研究院的教员,阿图尔阿迪,博士学位。“在Biocogniv,我们推进急症护理成为未来,大多数的死亡是避免,利用最先进的人工智能实验室数据。我们的新投资者的口径和顾问证明了这项工作的重要性。“使用真实的实验室数据从数以百计的医院和战略合作伙伴,Biocogniv创造了aiMarkers™,人工智能预测模型,可以检测急性条件之前就变得不可逆转,和倾斜™,实时,基于云计算平台,部署这些模型在临床护理。该公司将使用新的资金进一步发展和验证其aiMarkers™和倾斜™平台。“aiMarkers™是另一个例子医疗的AI的尚未开发的潜力。Biocogniv敏捷团队一直解决困难的问题参与将这一创新临床实践,吸引关键行业合作伙伴和思想领袖。 As long-term believers in the disruptive power of AI in healthcare, we couldn’t be more excited to join forces with them,” said venture capital pioneer Jim Breyer, founder and CEO of Breyer Capital. “Many companies are building AI for patient care, often without the proper rigor and clinical validation required for broad adoption in medicine,” said Leo Grady, PhD, CEO-in-Residence at Breyer Capital, who spearheaded the first FDA approval for an AI product in pathology as CEO of Paige.AI. “I am impressed with the results and progress that Biocogniv was able to achieve in a short period of time and I look forward to helping the company in this next phase.” About Breyer Capital Breyer Capital is a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs in the US and China. Founded by legendary investor Jim Breyer in 2006, Breyer Capital makes long-term, idea-driven strategic investments in artificial intelligence, digital health, data analytics, social media, and financial technologies. The firm prides itself on maintaining an openness to experimentation that can lead to long-term breakthrough performance and partnering with founders and teams who are passionate about building transformative companies anchored in technology. For more information, please visit http://www.breyercapital.com . About Biocogniv Biocogniv is the world’s first digital diagnostic company tackling time-critical conditions using artificial intelligence on top of laboratory data. The company’s software platform, clinOS™, is already connected to multiple hospital systems across the US, processing thousands of laboratory tests per day, and its pipeline of aiMarkers™ includes predictors for sepsis, respiratory failure, acute heart failure, and others. For more information, please visit http://www.biocogniv.com . Address: